Your Search Returned 34 tagged news reports
Blood plasma group CSL has settled a long running court battle in the United States over allegations it was involved in price fixing for life-saving plasma products, and has agreed to pay $US64 million ($67.9 million) to a number of American and
Hizentra, which is claimed to the first and only 20% subcutaneous immunoglobulin therapy, is indicated as replacement therapy in patients over 2 years old with primary immunodeficiency. The liquid drug maintains serum immunoglobulin G (IgG) levels
The blood products and vaccine supplier declared an unfranked final dividend of 52 cents per share to be paid on October 4. CSL also appointed a new director, Marie McDonald, after Ian Renard said he would retire from the company's board. more to
Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and similar products.
Berinert is additionally indicated for the treatment of acute HAE attacks at all body sites in adults and children in Europe. Eligible and trained patients could even self administer the therapy by intravenous infusion. CSL Behring research and
CSL Behring is pleased to continue its leadership in the development of innovative Ig therapies by providing Privigen to address the treatment needs of patients with this rare disorder," Romberg added.
P CSL Behring has commenced the patient enrollment in pivotal pediatric Phase III hemophilia B study of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The study is designed to assess rIX-FP's safety,
CSL Behring has teamed up with Professional Supercross racer Carl Schlacht to launch www.IamaChamPIon.com . PI can pose. "PI is a genetic disorder that can have a dramatic impact on a person's ability to participate in daily activities due to a
CSL is constructing a new plant at Broadmeadows which will increase production for export and has also added a biotech facility, which it will use to produce trial products for bleeding disorders. The biotech plant is being validated and next year we
Managing director Brian McNamee said the improved forecast was largely underpinned by the performance of CSL Behring, a US subsidiary, which supplies antibodies to treat immune deficiencies and rare diseases. A number of factors have contributed,